Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orasi Medical Expands To Tokyo
Orasi Medical has opened its new Tokyo office. The new office is expected to allow Orasi Medical to aid Japanese pharmaceutical companies in developing medicines for CNS diseases
Orasi Medical has opened its new Tokyo office. The new office is expected to allow Orasi Medical to aid Japanese pharmaceutical companies in developing medicines for CNS diseases
CytRx has initiated dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX injection in patients with relapsed acute promyelocytic leukemia (APL). According to CytRx, there
Vical has announced the results from a four-month interim analysis in an ongoing phase 2 trial for TransVax therapeutic cytomegalovirus (CMV) DNA vaccine. The results were presented at
Elan has cured breach of its Tysabri collaboration agreement with Biogen that had been identified by the US District Court for the Southern District of New York. Elan’s
Adamas Pharmaceuticals’ vitro study of its triple combination antiviral drug (TCAD) therapy showed greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double
Alcon has entered into an agreement to acquire ESBATech. Alcon will pay ESBATech shareholders $150m in cash at closing, plus contingent payments of up to $439m based upon
Gilead Sciences (Gilead) has published data from DAR-311 (DORADO), a phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) – darusentan, as an add-on
Merck has studied Isentress in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL), and at improving CD4 cell counts in previously
Tobira Therapeutics has revealed results from an in-vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL), using
Nektar Therapeutics’ clinical study data demonstrated that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions. NKTR-118 is